Provision of Haemophilia Advanced Therapy Medicinal Product (ATMP) Treatment Hubs

Concepts

• health services
• leeds
• england
• treatment hubs
• haemophilia gene therapy atmps
• haemophilia types
• providers of haemophilia atmp treatment hubs
• agene therapy service
• haemophilia atmp treatment hubs forpatients
• haemophilia atmp treatmenthubs

Location

East of England:

Description

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf ofNHS England (referred to as the Commissioner), is inviting suitably qualified andexperienced providers to respond to this invitation to tender (ITT) exercise to commissionhaemophilia Advanced Therapy Medicinal Product (ATMP) treatment hubs.The haemophilia ATMP treatment hub allocation model is as follows:Lot 1 – One site to cover the NHS England population in the East of EnglandLot 2 - Two sites to cover the NHS England population in LondonLot 3 – One site to cover the NHS England population in the MidlandsLot 4 – One site to cover the NHS England population in the North East of England andYorkshireLot 5 – One site to cover the NHS England population in the North West of EnglandLot 6 – One site to cover the NHS England population in the South East of EnglandLot 7 - One site to cover the NHS England population in the South West of EnglandPlease note that providers must be located in the defined geographical catchment area(s) that they are interested in providing services to. The key objectives of the Procurement are to commission Haemophilia ATMP treatmenthubs for patients with haemophilia types A and B to serve the population of England, and toensure that:• the providers of Haemophilia ATMP treatment hubs have the correct qualifications andgovernance arrangements in place to provide these treatments for the NHS in England, and• the Commissioner is offering services that are safe and of a high standard whilst fulfillingthe Commissioner’s public duty to provide services that are cost-effective.The National Institute for Health and Care Excellence (NICE) will be assessing a number ofATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expectedNICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs forpatients with haemophilia types A and B. NHS England is seeking to commission eight of the18 adult Comprehensive Care Centres (CCCs) in England to become ‘haemophilia ATMPtreatment hubs’. These hubs will deliver the haemophilia gene therapy ATMPs approved byNICE with a contract duration of 8 years with the option to extend for up to a further 18months.For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,NHS England will work with the UKHCDO to develop a thorough care pathway detailing theresponsibilities of both the hubs and spokes as well as referral and monitoring guidelines tomanage the care of haemophilia patients undergoing ATMP treatment.Given the significant amount of preparatory work that needs to be undertaken to deliver agene therapy service, it is not feasible for commissioners and providers to wait until NICE hasmade its recommendations to commence commissioning activity.Providers are therefore submitting bids to deliver a service ‘at risk’: it may be the case thatthe product does not receive a positive NICE recommendation.Providers wishing to be considered for the delivery of these services will need to respond tothe provider selection documentation and submit responses prior to the deadline stated inthis notice.The ITT documentation including a questionnaire is available through the Atamis (HealthFamily) portal: https://health-family.force.com/s/Welcome. The reference is C153405 andthe closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.There will also be an opportunity to attend a market engagement event via Microsoft Teamsat 11.30am on Thursday 20th April 2023. If you would like to participate in this event, pleaseemail josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides andquestions and responses will be made available to all bidders following the event.

Lot Division

Renewal Options

As a result of this procurement exercise an agreement will be established with the successfulBidders for a period of 8 years with the Commissioner having the option to extend theContract for up to a further 18 months. It is anticipated that the contract start date will be16th December 2023 which is 90 days following the expected final NICE guidance; however,this may be subject to change.

CPV Codes

• 85100000 - Health services

Indicators

• Restrictions apply to the lot award allocation.
• This is a one-off contract (no recurrence)
• Options are available.
• Renewals are not available.
• Professional qualifications are sought.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. **